Statins plus ezetimibe in the era of proprotein convertase subtilisin/ kexin type 9 inhibitors
نویسندگان
چکیده
منابع مشابه
Statins, plasma proprotein convertase subtilisin/kexin type 9 concentrations, and LDL lowering.
The discovery in 2003 that variants in the PCSK9 (proprotein convertase subtilisin/kexin type 9) gene cause autosomal dominant hypercholesterolemia revealed a new aspect of LDL cholesterol (LDL-C) metabolism (1). PCSK9, a protein of 692 amino acid residues produced at high concentrations in the liver, kidney, and intestine, has profound effects on LDL-C concentrations (2). Both gain-of-function...
متن کاملPCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future.
Reduction in low-density lipoprotein cholesterol (LDL-C), mainly with statins, has decreased the risk of cardiovascular events over the last few decades. However, there are several patient populations that warrant further decrease in LDL-C by additional cholesterol-lowering therapy other than statins. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a new class of drugs that...
متن کاملIncreased Risk of Adverse Neurocognitive Outcomes With Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors.
BACKGROUND There is encouraging evidence of the efficacy of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors; however, their long-term safety remains unclear. We performed a meta-analysis of studies to evaluate the long-term safety of PCSK9 inhibitors. METHODS AND RESULTS Our search strategy yielded 11 studies (9 smaller early-phase and 2 larger outcome trials). The outcomes a...
متن کاملInhibition of proprotein convertase subtilisin/kexin type 9 in the treatment of hypercholesterolemia.
Según datos de la Organización Mundial de la Salud, la enfermedad cardiovascular de origen isquémico o arterioscleroso (ECVA) es la primera causa de muerte en el mundo y especialmente en los países desarrollados. La aterosclerosis es una enfermedad arterial multifactorial, en la que el depósito en el espacio subendotelial de las lipoproteínas que transportan apolipoproteína B y colesterol, prin...
متن کاملRole of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9.
OBJECTIVE Proprotein convertase subtilisin/kexin type 9 (PCSK9), which binds the low-density lipoprotein receptor and targets it for degradation, has emerged as an important regulator of serum cholesterol levels and cardiovascular disease risk. Although much work is currently focused on developing therapies for inhibiting PCSK9, the endogenous regulation of PCSK9, particularly by insulin, remai...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Kardiologia Polska
سال: 2020
ISSN: 1897-4279,0022-9032
DOI: 10.33963/kp.15529